VRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Valeant Pharmaceuticals International Inc's revenue for the three months ended in Sep. 2016 was $2,480 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2016 was $10,029 Mil. Valeant Pharmaceuticals International Inc's revenue per share for the three months ended in Sep. 2016 was $7.10. Its revenue per share for the trailing twelve months (TTM) ended in Sep. 2016 was $29.03.
Valeant Pharmaceuticals International Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Valeant Pharmaceuticals International Inc was 7.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 54.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 49.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 19.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using revenue per share data.
During the past 13 years, Valeant Pharmaceuticals International Inc's highest 3-Year average Revenue per Share Growth Rate was 55.30% per year. The lowest was -10.80% per year. And the median was 27.20% per year.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Valeant Pharmaceuticals International Inc Revenue for the trailing twelve months (TTM) ended in Sep. 2016 was 2757.2 (Dec. 2015 ) + 2371.6 (Mar. 2016 ) + 2420.2 (Jun. 2016 ) + 2479.6 (Sep. 2016 ) = $10,029 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Valeant Pharmaceuticals International Inc Annual Data
Valeant Pharmaceuticals International Inc Quarterly Data